ARTICLE | Clinical News
Synribo omacetaxine mepesuccinate regulatory update
October 29, 2012 7:00 AM UTC
FDA granted accelerated approval to an NDA from Teva for Synribo omacetaxine mepesuccinate to treat chronic or accelerated phase chronic myelogenous leukemia in patients who have resistance and/or int...